KPV

Investigated uses

• Wound healing and inflammatory conditions in preclinical/FDA review contexts.

Mechanism and hypotheses

• KPV is an alpha-MSH-derived tripeptide; no human clinical administration evidence was identified in the FDA review.
• Hypothesized: Anti-inflammatory and wound-healing effects are laboratory/preclinical hypotheses.

Human evidence

• FDA found no human clinical studies supporting the reviewed KPV uses. Limitations: Absence of human administration data prevents estimating efficacy, incidence of adverse events or a safe dose.

Safety highlights

• No controlled human adverse-event incidence exists.
• Immunogenicity, impurities and route-specific risks remain unresolved.

Regulatory context

No FDA-approved KPV drug was identified. In July 2026, PCAC recommended KPV-related bulk drug substances for possible inclusion on the 503A Bulks List for wound healing and inflammatory conditions. The recommendation is nonbinding and was not a final FDA listing as of August 9, 2026.